ReviewChronic diseases and translational medicine2026
Exploring the Anti-Diabetic Potential of Anthocyanins: From Biochemical Pathways to Human Trials.
Review in Chronic diseases and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) is a global health challenge with increasing prevalence rates, particularly in low- and middle-income countries. Anthocyanins (ACs) are potential bioactive compounds found in various fruits and vegetables, attracting the attention of researchers due to their possible role in managing diabetes and its complications. Studies have demonstrated the beneficial effects of ACs on blood sugar levels, insulin sensitivity, and glucose tolerance. These effects may be associated with multiple mechanisms, including increased glucose transporter type 4 (GLUT4) expression, enhanced glucose uptake, AMP-activated protein kinase (AMPK) and protein kinase C (PKC) phosphorylation, improved insulin sensitivity, activation of phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling, increased glutathione (GSH) synthesis, production of short-chain fatty acids (SCFAs), glucagon-like peptide-1 (GLP-1) secretion, induction of antioxidant enzymes, improved beta-cell functioning, and activation of insulin signaling pathways. The activity of enzymes (alpha amylase, glucosidase, and dipeptidyl peptidase-IV [DPP-IV]) and the expression of inflammatory biomarkers (tumor necrosis factor [TNF], IL6, and MCP1) are reduced. These findings suggest the potential of ACs as adjunctive therapies. However, further studies, including well-structured clinical trials, are needed to explore the optimal dosage and long-term efficacy of ACs in diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.